Related Experiment Videos
Progress toward a live attenuated human hepatitis A virus vaccine
Developments in Biological Standardization
|January 1, 1983
Summary
Researchers developed a live, attenuated hepatitis A virus (HAV) vaccine candidate. This vaccine showed promise in animal models, inducing immunity without significant adverse effects, paving the way for human trials.
Area of Science:
- Virology
- Vaccinology
- Immunology
Background:
- Human hepatitis A virus (HAV) was first cultured in vitro, facilitating vaccine development.
- HAV vaccine research is progressing via live-attenuated, inactivated, and recombinant approaches.
Purpose of the Study:
- To develop a live, attenuated HAV vaccine candidate.
- To assess the safety and immunogenicity of attenuated HAV variants in animal models.
Main Methods:
- HAV attenuation was achieved through serial passaging in rhesus monkey kidney cells and human diploid lung fibroblasts.
- Attenuated variants were evaluated for virulence, enzyme elevation, liver histology, and anti-HAV induction in marmosets and chimpanzees.
- Immunity was assessed by challenging vaccinated animals with virulent HAV.
Main Results:
- Several HAV variants demonstrated reduced virulence with desirable live vaccine properties, including retained immunogenicity and minimal adverse effects.
- Vaccinated animals exhibited solid immunity upon challenge with virulent HAV.
- A prototype inactivated HAV vaccine also induced immunity in marmosets.
Conclusions:
- Live-attenuated HAV vaccine candidates derived from cell culture show significant promise for preventing hepatitis A.
- Further development and preliminary human studies are planned for these experimental vaccines.